^
    1d
    Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial. (PubMed, Eur J Cancer)
    Obesity was associated with lower ORR with letrozole alone, whereas this association was not observed in patients treated with taselisib.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • IL6 (Interleukin 6)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    letrozole • taselisib (GDC-0032)
    1d
    Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. (PubMed, NPJ Breast Cancer)
    A transcriptional signature associated with SARM sensitivity was identified, primarily driven by proliferation-related processes, consistent with a significant decrease in S-phase cell cycle proteins upon treatment in EP0062-sensitive models. In some EP0062-resistant tumors, the combination with palbociclib enhanced the antitumor effect of EP0062, suggesting a potential strategy for metastatic patients with acquired ET resistance.
    Journal
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • GATA3 (GATA binding protein 3)
    |
    ER positive • PIK3CA mutation • PTEN mutation
    |
    Ibrance (palbociclib) • vosilasarm (EP0062)
    1d
    Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (clinicaltrials.gov)
    P2, N=134, Recruiting, Brigham and Women's Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    2d
    Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS) (clinicaltrials.gov)
    P=N/A, N=120, Suspended, Ohio State University Comprehensive Cancer Center | Recruiting --> Suspended
    Trial suspension
    2d
    MNCCTN: Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Oct 2026 --> Sep 2027 | Trial primary completion date: Oct 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    HER-2 positive • ER positive
    2d
    Design, synthesis, in vitro and in silico evaluation of novel 5-(1-benzyl-1H-indol-3-yl)-3-phenyl-4,5-dihydroisoxazole derivatives against ER-positive breast cancer. (PubMed, Bioorg Chem)
    Compounds 19 and 21 underscored significant human ERα inhibition in contrast to tamoxifen and bazedoxifene...Moreover, pharmacokinetics and DFT analysis ensured drug-likeness and bio-feasibility of promising molecules. Finally, based on interaction-analysis, bio-assay findings, and 3D-QSAR mapping, an overall structure-activity correlation was established for future-optimization and lead-development of indole - 4,5-dihydroisoxazole hybrids against ER+ BC.
    Preclinical • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    tamoxifen
    2d
    Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=63, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel
    2d
    The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors (clinicaltrials.gov)
    P=N/A, N=1, Completed, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    2d
    Breast 54: Focused Ultrasound and Gemcitabine in Breast Cancer (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Patrick Dillon, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint®
    |
    gemcitabine
    3d
    REMIND1: Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore (clinicaltrials.gov)
    P=N/A, N=12750, Enrolling by invitation, National University Hospital, Singapore
    New trial
    3d
    Anastrozole-Induced Tumor Lysis Syndrome in Breast Cancer: A Case Report of a Rare Critical Care Emergency. (PubMed, Case Rep Oncol)
    Despite aggressive critical care management, she experienced cardiac arrest and died. This case may represent the first reported fatal occurrence of anastrozole-associated TLS in advanced breast cancer, underscoring the need for vigilance for TLS even with hormonal agents traditionally considered low-toxicity.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    anastrozole
    3d
    A Study of a Side Effects and Resource Navigation Program for People With Cancer (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Memorial Sloan Kettering Cancer Center
    New trial • Adverse events